Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 ADMIRAL trial Meeting Abstract
| Authors: | Perl, A. E.; Martinelli, G.; Cortes, J. E.; Neubauer, A.; Berman, E.; Paolini, S.; Montesinos, P.; Baer, M. R.; Larson, R. A.; Ustun, C.; Fabbiano, F.; Di Stasi, A.; Stuart, R.; Olin, R.; Kasner, M.; Ciceri, F.; Chou, W. C.; Podoltsev, N.; Recher, C.; Yokoyama, H.; Hosono, N.; Yoon, S. S.; Lee, J. H.; Pardee, T.; Fathi, A. T.; Liu, C.; Liu, X.; Bahceci, E.; Levis, M. J. |
| Abstract Title: | Gilteritinib significantly prolongs overall survival in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: Results from the phase 3 ADMIRAL trial |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 42 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2019 Oct 11-14 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2019-10-01 |
| Start Page: | 295 |
| Language: | English |
| ACCESSION: | WOS:000568159600708 |
| PROVIDER: | wos |
| DOI: | 10.1159/000502425 |
| Notes: | "Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology" -- Meeting Abstract: V1021 -- Source: Wos |
